2018-2026年免疫學領域的合作與授權協議

利用 919 項現有合作關係和許可協議的訊息，了解免疫學領域合作的趨勢。

《2018-2026 年免疫學領域的合作與許可協議》提供了有關 919 項與免疫學相關資產、技術和開發計劃的合作交易的全面資訊。

免疫學是生命科學領域內極為廣泛且合作活躍的領域，涵蓋多種疾病領域、作用機制、治療技術和研發階段。其交易結構不僅反映了該領域的科學多樣性，也反映了各公司為獲取、開發和商業化創新成果所採取的不同策略。

本報告將這些趨勢匯總到一個資訊來源中，使用戶能夠了解哪些公司正在合作，哪些免疫學機會正在吸引關注，交易結構是什麼，披露了哪些財務條款，以及交易如何根據治療適應症、技術和開發階段而有所不同。

這份報告不只是簡單地列出了交易清單；它結合了全面的市場交易分析和財務基準、主要交易商的信息、詳細的交易記錄以及公開的合約文件。

本報告為免疫學領域負責人中的業務發展、許可、研究和評估、公司策略、研發策略、競爭情報分析和法律團隊提供可操作的資訊和基準資源。

了解免疫學領域的合作趨勢

本報告分析了2018年至2026年免疫學領域的交易情況，內容包括：

• 免疫學領域合作的年度趨勢
• 按交易類型分類的交易趨勢
• 產業部門
• 合作關係發展階段
• 技術類型
• 治療指徵
• 免疫學領域最活躍的交易商
• 根據已揭露的交易金額，主要交易金額
• 免疫學領域合作活動的趨勢
• 這使用戶能夠確定他們的活動集中在哪些方面，並了解哪些公司、技術、開發階段和治療領域正在吸引合作興趣。
• 免疫學領域合作關係的財務狀況基準分析
• 財務條款可能因所涉資產、開發階段、技術、授予的權利以及交易的整體結構而有很大差異。

本報告對已揭露的財務狀況進行了以下專案分析：

• 交易總額
• 預付款
• 里程碑付款
• 版稅率
• 透過分析這些基準背後的具體交易，用戶可以更全面地了解所揭露的經濟數據背後的經濟狀況。
• 這為內部基準測試、機會評估、交易準備和談判提供了一個現實的基準。
• 財務基準最有用的解讀方式不是將其視為獨立的平均值，而是將其與類似交易的結構和情況結合起來解讀。本報告提供了建立這種背景所需的基礎交易資訊。
• 確定免疫學領域的關鍵交易商和潛在的未來合作夥伴。
• 本報告列出了在免疫學領域合作活動最活躍的公司，並提供交易歷史記錄，以便用戶可以調查這些公司過去的活動。

這有助於用戶識別以下內容：

• 積極尋求免疫學領域機會的公司
• 潛在的許可和合作研究合作夥伴
• 我們曾多次在相關疾病領域與之合作的組織
• 積極參與開發過程的公司
• 對特定機制、技術或治療方法感興趣的交易商
• 競爭對手正在推廣相關的外部創新策略
• 對於在免疫學領域尋求資產和技術合作夥伴的公司而言，過去的交易歷史可以提供寶貴的見解，了解哪些組織對類似的機會表現出了興趣。
• 依免疫學適應症和標靶比較合作趨勢。
• 免疫學涵蓋了廣泛的治療適應症和生物標的都有其獨特的科學、臨床和商業性趨勢。
• 本報告按治療適應症和治療標靶分析合作關係，使用戶能夠專注於與特定項目和策略利益最相關的交易，而不是僅依賴廣泛的免疫學基準。
• 透過結合基於技術和發展階段的分析，用戶可以發現更多有意義的類似交易和潛在的未來合作夥伴關係。
• 了解免疫學領域的合約結構
• 本報告包括聯合研究、授權、開發、調查和其他合作交易。

根據交易詳情和資訊披露，用戶可以調查以下方面：

• 授予和保留的權利
• 研發職責
• 授權權
• 獨家版權
• 區域權利
• 智慧財產
• 發展和監管義務
• 負責生產和供應
• 商業化權利
• 金錢補償
• 里程碑和版稅
• 管治
• 合約期限和終止條款
• 這些例子對於考慮免疫學領域合作的適當框架將很有用。
• 從實際合約文件中學習
• 本報告提供了公開可用的有關所選免疫學領域交易的基礎合約文件的存取權限。

這些合約提供的資訊遠比簡單的標題公告所能展現的要詳細得多，使用戶能夠檢驗公司如何記錄諸如以下事項：

• 權利範圍
• 發展義務
• 智慧財產
• 獨家版權
• 財務狀況
• 里程碑觸發條件
• 特許權使用費規定
• 商業化權
• 合約終止及其他談判事項
• 對於正在準備和談判免疫學領域合作研究或許可協議的團隊來說，獲取實際的合約措辭可以提供關於類似交易實際結構方式的寶貴見解。
• 綜合免疫學交易目錄
• 本報告包含免疫學領域 919 項合作研究和授權協議的綜合目錄，為識別相關的領先交易提供了詳細的資訊來源。

在以下條件下可以查看交易記錄：

• 公司
• 技術類型
• 治療適應症或標靶
• 合約揭露狀態
• 每筆交易都與其底層交易記錄相關聯，從而可以存取詳細的交易資訊和相關的合約文件（如有）。
• 誰該使用這份報告？
• 業務拓展與授權團隊
• 找出類似的免疫學交易、潛在合作夥伴和相關交易結構。
• 研究與評估團隊
• 這使您能夠了解哪些公司正在積極探索免疫學領域的商機，涵蓋相關的適應症、技術、標靶和開發階段。
• 尋求合作夥伴的生技公司
• 找出對類似免疫學相關資產或技術表現出明確興趣的組織。
• 企業策略與研發策略團隊
• 我們將了解我們的競爭對手和潛在合作夥伴如何透過外部創新來建立其免疫學產品組合。
• 競爭情報與市場分析團隊
• 按公司、適應症、目標、開發階段和技術追蹤合作趨勢，以了解不斷變化的策略重點。
• 法律及交易團隊
• 我們將仔細審查公開的合約和以往的合約結構，以幫助您準備和談判交易。
• 我們將市場範圍內的免疫學資訊轉化為公司特有的洞察。
• 符合資格的客戶將收到 Current Partnering 的報告，以及為經營團隊客製化的合作關係簡報。
• 本次簡報將把免疫學交易資訊應用於您自己的資產、技術、適應症、目標或合作目標。
• 根據您的需要，這可能包括相關的類似交易、有前景的合作夥伴、競爭對手的活動、發展階段分析、交易結構、財務基準、忠誠度分析、合約見解以及其他專門為您情況選擇的資訊。
• 請索取樣本或聯絡 Current Partnering 討論報告內容以及我們是否可以為貴公司提供客製化分析。

目錄

執行摘要

第1章：引言

第2章：免疫學領域的交易趨勢

• 免疫學領域合作的過去趨勢
• 免疫學領域按交易類型分類的合作關係
• 免疫學領域的產業特定合作關係
• 免疫學領域不同發展階段的合作
• 按技術類型分類的免疫學領域合作
• 基於治療適應症的免疫學領域合作

第3章 免疫學領域合夥企業的財務條件

• 已揭露免疫學領域合作的財務條款
• 免疫學領域合作協議的總價值
• 免疫學領域合約中的預付款
• 免疫學領域合作的里程碑付款
• 免疫學領域的忠誠度

第4章：免疫學領域的主要交易與交易商

• 在免疫學領域開展合作最活躍的公司
• 免疫學領域最活躍的交易商名單
• 免疫學主要領域的交易量：以價值

第5章：免疫學領域合約文件目錄

• 免疫學領域的合作項目，且已有相關合約文件。

第6章：基於治療標靶的免疫學領域交易

• 基於免疫學治療標靶的交易
• 交易目錄
• 交易目錄 - 免疫學領域的交易記錄，按字母順序（A-Z）排序
• 交易目錄 - 按技術類型分類的免疫學領域交易
• 交易類型的定義
• 關於生物製藥研究
• Current Partnering
• Current Agreements
• 理想合作夥伴近期報告標題

Understand the immunology partnering landscape using intelligence from 919 real-world collaboration and licensing deals.

Immunology Collaboration and Licensing Deals 2018-2026 provides comprehensive intelligence on 919 partnering deals involving immunology assets, technologies and development programs.

Immunology is a broad and highly active area of life sciences partnering, encompassing multiple disease areas, mechanisms of action, therapeutic technologies and stages of development. Deal structures reflect both the scientific diversity of the field and the different strategies companies use to access, develop and commercialize innovation.

The report brings this activity together in one resource, enabling users to understand who is partnering, which immunology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in immunology partnering.

Understand the immunology partnering landscape

The report analyzes immunology dealmaking from 2018 to 2026, including:

• Trends in immunology partnering by year
• Deal activity by deal type
• Industry sector
• Stage of development at the time of partnering
• Technology type
• Therapeutic indication
• Most active immunology dealmakers
• Leading deals by disclosed value
• How immunology partnering activity is evolving
• This enables users to identify where activity is concentrated and understand which companies, technologies, development stages and therapeutic areas are attracting partnering interest.
• Benchmark immunology deal financials
• Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.

The report provides dedicated analysis of disclosed financial terms, including:

• Headline deal values
• Upfront payments
• Milestone payments
• Royalty rates
• Users can investigate the individual transactions behind these benchmarks to understand the wider context surrounding the disclosed economics.
• This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
• Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
• Identify leading immunology dealmakers and prospective partners
• The report identifies the most active companies in immunology partnering and provides transaction histories that enable users to investigate their previous activity.

This can help users identify:

• Companies actively seeking immunology opportunities
• Prospective licensing and collaboration partners
• Organizations repeatedly partnering in relevant disease areas
• Companies active at relevant stages of development
• Dealmakers demonstrating interest in particular mechanisms, technologies or therapeutic approaches
• Competitors pursuing related external innovation strategies
• For companies seeking to partner an immunology asset or technology, previous transaction activity can provide valuable evidence of which organizations have demonstrated an appetite for comparable opportunities.
• Compare partnering activity across immunology indications and targets
• Immunology encompasses a wide range of therapeutic indications and biological targets with differing scientific, clinical and commercial dynamics.
• The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad immunology benchmarks and focus on transactions most relevant to a particular program or strategic interest.
• Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
• Understand how immunology agreements are structured
• The report includes collaboration, licensing, development, research and other partnering transactions.

Depending on the transaction and available disclosure, users can investigate areas including:

• Rights granted and retained
• Research and development responsibilities
• Licensing rights
• Exclusivity
• Geographic rights
• Intellectual property
• Development and regulatory obligations
• Manufacturing and supply responsibilities
• Commercialization rights
• Financial consideration
• Milestones and royalties
• Governance
• Term and termination provisions
• These real-world examples provide useful reference points when considering the appropriate structure for an immunology partnership.
• Learn from real-world contract documents
• Where publicly available, the report provides access to underlying contract documents for selected immunology transactions.

These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:

• Scope of rights
• Development obligations
• Intellectual property
• Exclusivity
• Financial terms
• Milestone triggers
• Royalty provisions
• Commercialization rights
• Termination and other negotiated provisions
• For teams preparing or negotiating an immunology collaboration or licensing agreement, access to real contract language provides valuable insight into how comparable deals have been structured in practice.
• Comprehensive immunology deal directory
• The report includes a comprehensive directory of 919 immunology collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.

Deals can be reviewed by:

• Company
• Technology type
• Therapeutic indication or target
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable immunology transactions, prospective partners and relevant deal structures.
• Search and Evaluation teams
• Understand which companies are actively seeking immunology opportunities across relevant indications, technologies, targets and development stages.
• Biotechnology Companies Seeking Partners
• Identify organizations with demonstrated interest in comparable immunology assets and technologies.
• Corporate and R&D Strategy teams
• Understand how competitors and prospective partners are building immunology portfolios through external innovation.
• Competitive and Market Intelligence teams
• Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
• Legal and Transaction teams
• Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
• Turn market-wide immunology intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying immunology deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in immunology dealmaking

• 2.1. Introduction
• 2.2. Immunology partnering over the years
• 2.3. Immunology partnering by deal type
• 2.4. Immunology partnering by industry sector
• 2.5. Immunology partnering by stage of development
• 2.6. Immunology partnering by technology type
• 2.7. Immunology partnering by therapeutic indication

Chapter 3 - Financial deal terms for immunology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for immunology partnering
• 3.3. Immunology partnering headline values
• 3.4. Immunology deal upfront payments
• 3.5. Immunology deal milestone payments
• 3.6. Immunology royalty rates

Chapter 4 - Leading immunology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in immunology partnering
• 4.3. List of most active dealmakers in immunology
• 4.4. Top immunology deals by value

Chapter 5 - Immunology contract document directory

• 5.1. Introduction
• 5.2. Immunology partnering deals where contract document available

Chapter 6 - Immunology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by immunology therapeutic target
• Deal directory
• Deal directory - Immunology deals by company A-Z
• Deal directory - Immunology deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Immunology partnering since 2018
• Figure 2: Immunology partnering by deal type since 2018
• Figure 3: Immunology partnering by industry sector since 2018
• Figure 4: Immunology partnering by stage of development since 2018
• Figure 5: Immunology partnering by technology type since 2018
• Figure 6: Immunology partnering by indication since 2018
• Figure 7: Immunology deals with a headline value
• Figure 8: Immunology deals with upfront payment values
• Figure 9: Immunology deals with milestone payment
• Figure 10: Immunology deals with royalty rates
• Figure 11: Active immunology dealmaking activity since 2018
• Figure 12: Top immunology deals by value since 2018